tigulixostat (LC350189) / LG Chem 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
5 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tigulixostat (LC350189) / LG Chem
EURELIA1, NCT05586958: Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients

Recruiting
3
350
US
Tigulixostat, LC350189, Placebo
LG Chem
Gout, Hyperuricemia, Gout Flare, Tophi
12/24
06/25
EURELIA2, NCT05586971: Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients

Recruiting
3
2542
US
Tigulixostat, LC350189, Allopurinol, Placebo
LG Chem
Gout, Hyperuricemia, Gout Flare, Tophi
07/25
12/25
NCT06501534: A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects

Active, not recruiting
2
84
RoW
Febuxostat, IBI128
Innovent Biologics (Suzhou) Co. Ltd.
Gout, Hyperuricemia
01/25
02/25
NCT06189404: Effect of Tigulixostat on the Pharmacokinetics of Theophylline

Completed
1
24
US
Tigulixostat, LC350189, Theophylline
LG Chem
Gout, Hyperuricemia
11/23
11/23
NCT06277752: A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor)

Completed
1
30
RoW
dose-5 group, dose-1 group, dose-2 group, dose-4 group, dose-3 group
Innovent Biologics (Suzhou) Co. Ltd.
Gout Arthritis
03/24
03/24

Download Options